Committee on Energy and Commerce U.S. House of Representatives Witness Disclosure Requirement - "Truth in Testimony" Required by House Rule XI, Clause 2(g)

1.	Your Name: Bradley Merrill Thompson		
2.	Are you testifying on behalf of the Federal, or a State or local	Yes	No
	government entity?		X
3.	Are you testinying on benan of an entry that is not a government	Yes	No
L_	entity?		
4.	Other than yourself, please list which entity or entities you are representing		
	mHealth Regulatory Coalition		
5.	Please list any Federal grants or contracts (including subgrants or subcontr	racts) t	hat
	you or the entity you represent have received on or after October 1, 2011:		
	Net applicable		
	Not applicable		
6.	If your answer to the question in item 3 in this form is "yes," please describe	e your	
	position or representational capacity with the entity or entities you are repr	resentii	ng:
	General Counsel for the mHealth Regulatory Coalition		
7.	If your answer to the question in item 3 is "yes," do any of the entities	Yes	No
1.1	A your anone to the quebeen in the set of th	1 05	110
8	disclosed in item 4 have parent organizations, subsidiaries, or		_
6	disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony?		×
8.	disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony? If the answer to the question in item 3 is "yes," please list any Federal grant	ts or	×
	disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony?If the answer to the question in item 3 is "yes," please list any Federal grant contracts (including subgrants or subcontracts) that were received by the end	ts or entities	× listed
	disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony? If the answer to the question in item 3 is "yes," please list any Federal grant contracts (including subgrants or subcontracts) that were received by the en under the question in item 4 on or after October 1, 2011, that exceed 10 per	ts or entities rcent of	X listed f the
	disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony? If the answer to the question in item 3 is "yes," please list any Federal grant contracts (including subgrants or subcontracts) that were received by the en under the question in item 4 on or after October 1, 2011, that exceed 10 per revenue of the entities in the year received, including the source and amoun	ts or entities rcent of	X listed f the
	disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony? If the answer to the question in item 3 is "yes," please list any Federal grant contracts (including subgrants or subcontracts) that were received by the en under the question in item 4 on or after October 1, 2011, that exceed 10 per	ts or entities rcent of	X listed f the
	disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony? If the answer to the question in item 3 is "yes," please list any Federal grant contracts (including subgrants or subcontracts) that were received by the en under the question in item 4 on or after October 1, 2011, that exceed 10 per revenue of the entities in the year received, including the source and amoun grant or contract to be listed: Not applicable	ts or entities rcent of	X listed f the
	disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony? If the answer to the question in item 3 is "yes," please list any Federal grant contracts (including subgrants or subcontracts) that were received by the en under the question in item 4 on or after October 1, 2011, that exceed 10 per revenue of the entities in the year received, including the source and amoun grant or contract to be listed: Not applicable	ts or entities rcent of	X listed f the
8.	disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony? If the answer to the question in item 3 is "yes," please list any Federal grant contracts (including subgrants or subcontracts) that were received by the en under the question in item 4 on or after October 1, 2011, that exceed 10 per revenue of the entities in the year received, including the source and amoun grant or contract to be listed: Not applicable	ts or entities rcent of	X listed f the
8.	disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony? If the answer to the question in item 3 is "yes," please list any Federal grant contracts (including subgrants or subcontracts) that were received by the en under the question in item 4 on or after October 1, 2011, that exceed 10 per revenue of the entities in the year received, including the source and amoun grant or contract to be listed: Not applicable	ts or entities rcent of	X listed f the
8.	disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony? If the answer to the question in item 3 is "yes," please list any Federal grant contracts (including subgrants or subcontracts) that were received by the en under the question in item 4 on or after October 1, 2011, that exceed 10 per revenue of the entities in the year received, including the source and amoun grant or contract to be listed: Not applicable	ts or entities rcent of	X listed f the
8.	disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony? If the answer to the question in item 3 is "yes," please list any Federal grant contracts (including subgrants or subcontracts) that were received by the en- under the question in item 4 on or after October 1, 2011, that exceed 10 per revenue of the entities in the year received, including the source and amoun grant or contract to be listed: Not applicable Please attach your curriculum vitae to your completed disclosure form.	ts or entities rcent of nt of ea	X listed f the
8 . 9 .	disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony? If the answer to the question in item 3 is "yes," please list any Federal grant contracts (including subgrants or subcontracts) that were received by the en under the question in item 4 on or after October 1, 2011, that exceed 10 per revenue of the entities in the year received, including the source and amoun grant or contract to be listed: Not applicable	ts or entities rcent of nt of ea	X listed f the

EPSTEIN BECKER & GREEN, P.C.

ATTORNEYS AT LAW

Bradley Merrill Thompson is a shareholder in the Indianapolis office of the law firm of Epstein Becker & Green, P.C. There he counsels medical device, drug, combination product and biotechnology companies on a wide range of FDA regulatory, reimbursement and clinical trial issues. At the firm, Mr. Thompson leads the Medical Device Regulatory Practice, the Clinical Trials Practice and the Connected Health Practice, and serves on the firm's Health & Life Sciences Steering Committee.

For trade associations, Mr. Thompson has served as counsel to AdvaMed and the Continua Health Alliance, as General Counsel to the Combination Products Coalition, the mHealth Regulatory Coalition and the CDS Coalition and as General Counsel and Secretary for the Indiana Medical Device Manufacturers Council.

Connected Health Practice

In EBG's Connected Health Practice, Mr. Thomspon focuses on the federal regulatory requirements—FDA, reimbursement, privacy and others—that impact remote monitoring, mobile health, HIT and device interoperability. The firm's Connected Health Practice brings together a multidisciplinary team of attorneys and consultants trained and experienced in Medicare and private insurance payment, regulatory, scientific, IT, clinical, and security disciplines. Mr. Thompson conducts educational programs on connected health regulation and blogs for Mobihealthnews.com.

Teaching, Writing and Serving

Mr. Thompson has taught food & drug law at Indiana University School of Law-Indianapolis and Columbia Law School. He also serves on the editorial boards for *Medical Device & Diagnostic Industry* (1993-present), *Food & Drug Law Journal* (2007 – 2011) and BNA's *Medical Device Law & Industry Report* (2007-present).

Mr. Thompson also has served as Co-Chair of the Food & Drug Law Committee of the Administrative Law Section of the American Bar Association, and as Co-Chair of the Medical Device Committee of FDLI.

Mr. Thompson has written extensively on the topics of medical device regulation, including:

- A book entitled FDA's Regulation of Medical Devices (Interpharm Press, 1995),
- A chapter on Analyte Specific Reagents in an FDLI book on laboratory diagnostics,
- A chapter on Diagnostics for a book on medical device law for the Practicing Law Institute.,
- An ebook on FDA Regulation of mHealth, published by mobihealthnews.com,

- A chapter in "Off-Label Communications: A Guide to Sales and Marketing Compliance" published by FDLI (2008-2009), and
- A chapter in "Guide to Medicare Coverage Decision-making and Appeals" published by the American Bar Association (2002).

Mr. Thompson also has published dozens of articles and is a frequent speaker at educational conferences. A full list of publications and other planners is available on the law firm's <u>website</u>.

Honors

Mr. Thompson was included in 100 Notable People in the Medical Device Industry (*Medical Device & Diagnostics Industry*, June 2004), has earned an AV rating in Martindale Hubble (its highest rating), has been named a "SuperLawyer" in Indiana and Washington, D.C., has been elected as a Fellow in the American Bar Foundation¹ and is listed in Chambers USA: A Guide to America's Leading Business Lawyers.

Education

Mr. Thompson received his B.A. *cum laude*, and an M.B.A. from the University of Illinois and his J.D. *cum laude* from the University of Michigan Law School.

¹ The Fellows is an honorary organization of attorneys, judges, law faculty, and legal scholars who have been elected by their peers. Membership is limited to one third of one percent of lawyers licensed to practice in each jurisdiction.